Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762162 | 1.00 | SLC1A1 (0.40) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL2917215 | 0.85 | GRM8 (0.58) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL435290 | 0.85 | GRM8 (0.58) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL2917216 | 0.85 | SLC1A1 (0.58) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL5053704 | 0.83 | SLC1A1 (0.34) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL8610972 | 0.83 | ALOX15 (0.59) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9250356 | 0.82 | LTA4H (0.43) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9250360 | 0.82 | LTA4H (0.43) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL9250366 | 0.82 | LTA4H (0.38) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL7717181 | 0.82 | SLC1A1 (0.54) | SLC1A1GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3827076-A1 | IN VIVO DELIVERY SYSTEM OF THE GENOME DNA MODIFYING ENZYMES AND THE USE THEREOF | Uniwersytet Jagiellonski (PL) | 2021-06-02 | — | — | EP | claimed |
| WO-2020021312-A1 | IN VIVO DELIVERY SYSTEM OF THE GENOME DNA MODIFYING ENZYMES AND THE USE THEREOF | UNIWERSYTET JAGIELLONSKI (PL) | 2020-01-30 | — | — | WO | claimed |
| EP-1406930-A2 | ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF | BIO-TECHNOLOGY GENERAL CORPORATION (US) | 2004-04-14 | — | — | EP | claimed |
| US-20040002450-A1 | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. (IL) | 2004-01-01 | — | — | US | claimed |
| US-20040001822-A1 | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. (IL) | 2004-01-01 | — | — | US | claimed |
| US-20040001839-A1 | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. (IL) | 2004-01-01 | — | — | US | claimed |
| WO-2002053700-A2 | ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF | BIO-TECHNOLOGY GENERAL CORP. (US) | 2002-07-11 | — | — | WO | claimed |
| EP-0959884-A4 | — | — | 1999-12-15 | — | — | EP | claimed |
| EP-0959884-A1 | PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1999-12-01 | — | — | EP | claimed |
| US-5856506-A | (OXAZOLYLCARBONYLAMINO)ETHYLAMINO GLUTAMATE DERIVATIVES | UNIVERSITY OF PITTSBURGH (US) | 1999-01-05 | — | — | US | claimed |
| WO-1998004257-A1 | PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1998-02-05 | — | — | WO | claimed |
| WO-2026090578-A1 | CDH17-BINDING ANTIBODIES AND METHODS OF USE THEREOF | Antharis Therapeutics Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731651-A1 | DUAL TRANSPORTERS AND METHODS OF USE | Denali Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4724458-A2 | PEPTIDE THERAPEUTICS | The Regents of the University of California (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4720114-A2 | ANTI-HBSAG ANTIBODY FOR TREATMENT OF CHRONIC HEPATITIS D | Bluejay Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20040001822-A1 | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. (IL) | 2004-01-01 | — | — | US | disclosed |
| US-20040002450-A1 | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. (IL) | 2004-01-01 | — | — | US | disclosed |
| EP-1363920-A1 | MODIFIED PSMA LIGANDS AND USES RELATED THERETO | Beth Israel Deaconess Medical Center (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002098885-A1 | MODIFIED PSMA LIGANDS AND USES RELATED THERETO | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002053700-A2 | ISOLATED MOLECULES COMPRISING EPITOPES CONTAINING SULFATED MOIETIES, ANTIBODIES TO SUCH EPITOPES, AND USES THEREOF | BIO-TECHNOLOGY GENERAL CORP. (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040001822-A1 | Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | CD47, CD14, SELE | SLC1A1 3678/4885GRM8 4109/4885GRM6 3332/4885 |
| US-20040001839-A1 | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | CD44, SELE, CD47 | SLC1A1 3182/4885GRM8 3734/4885GRM6 2902/4885 |
| US-20040002450-A1 | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | CD47, CD14, SELP | SLC1A1 4169/4885GRM8 3632/4885GRM6 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.